Nipotin 3000

Name: Nipotin 3000
SKU: SKU-OHZSdbiJ
Availability: InStock

Injection - 3000IU/0.75ml

Aristopharma Limited

Generic: Erythropoietin

1 Injection

Original price was: Tk. 1,400.Current price is: Tk. 1,246.

Description

Medicine Overview of Nipotin 3000 3000IU/0.75ml Injection

Introduction

Nipotin 3000 is a medicine that helps your bone marrow to produce more red blood cells. It is used to treat a type of anemia caused by kidney disease. It is also used to treat anemia caused by cancer chemotherapy and by taking medicines to treat HIV. Nipotin 3000 is given by injection either under the skin or into a vein which will be decided by your doctor. Usually the injections are given by a nurse or doctor. The dose depends on your body weight and the cause of your anemia. Iron supplements both before and during treatment may make

Uses of Nipotin 3000

Anemia due to chronic kidney disease
Anemia due to cancer chemotherapy

Side effects of Nipotin 3000

Common

High blood pressure
Nausea
Fever
Vomiting

How to use Nipotin 3000

Your doctor or nurse will give you this medicine. Kindly do not self administer.

How Nipotin 3000 works

Nipotin 3000 is an erythropoiesis-stimulating agent (ESA). It works by stimulating the bone marrow (soft tissue inside the bones which produces red blood cells) to produce more red blood cells.

What if you forget to take Nipotin 3000?

If you miss a dose of Nipotin 3000, please consult your doctor.

Quick Tips

Nipotin 3000 helps in the treatment of anemia that may have occurred due to chronic kidney disease or cancer chemotherapy.

It is given as a single injection under your skin.

Your doctor may get your blood tests done regularly to monitor the levels of hemoglobin, blood cells and electrolytes such as potassium in your blood.

Monitor your blood pressure regularly while taking this medication. Inform your doctor if you notice symptoms of very high blood pressure such as severe headache, problems with your eyesight, nausea, vomiting or fits (seizures).

Stop taking Nipotin 3000 and inform your doctor if you develop shortness of breath or skin rash.

Brief Description

Indication

Anemia associated with Chronic Renal Failure, including patients on dialysis (ESRD) and patients not on dialysis, Anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy, Anemic patients (hemoglobin > 10 to < 13 g/dL) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions, Anemia related to therapy with zidovudine in HIV-infected patients.

Adult Dose

Chronic Kidney Disease-Associated Anemia Reduction of need for red blood cell (RBC) transfusion in patients with chronic kidney disease (CKD) Patient not on dialysis: 50-100 units/kg IV/SC 3 times weekly initially Initiate only when (1) hemoglobin level <10 g/dL, (2) rate of hemoglobin decline indicates likely necessity of RBC transfusion, and (3) reducing risk of alloimmunization or other risks related to RBC transfusion is goal; if hemoglobin level >10 g/dL, reduce or interrupt dose and use lowest dose sufficient to reduce need for RBC transfusion Patient on dialysis: 50-100 units/kg IV 3 times weekly initially Initiate when hemoglobin level <10

Child Dose

Chronic Kidney Disease-Associated Anemia
<1 month: Safety and efficacy not established
>1 month: 50 units/kg IV/SC 3 times weekly initially; if patient on dialysis, IV route recommended

Initiate when hemoglobin level <10 g/dL; if hemoglobin level approaches or exceeds 11 g/dL, reduce or interrupt dose

Prematurity-Related Anemia
25-100 units/kg SC 3 times weekly or 200-400 units/kg SC/IV q24-48hr for 2-6 weeks

Zidovudine-Related Anemia
<8 months: Safety and efficacy not established
8 months-17 years: 50-400 units/kg SC/IV 2-3 times weekly

Chemotherapy-Related Anemia
<5 years: Safety and efficacy not established
5-18 years: 600 units/kg IV once weekly; not to exceed 40,000 units

Contraindication

Uncontrolled hypertension, hypersensitivity to mammalian cell products and human albumin.

Mode of Action

Erythropoietin regulates erythropoiesis by stimulating the differentiation and proliferation of erythroid precursors, stimulating the release of reticulocytes into the circulation, and synthesis of cellular haemoglobin. Recombinant human erythropoietin is available as epoetin alfa and epoetin beta which are used in the management of anaemias associated with CRF, cancer chemotherapy and anti-AIDS drug zidovudine.

Precaution

Erythropoietin should be used with caution in those patients with controlled hypertension, ischaemic vascular disease, history of seizures, or suspected allergy to the product. Iron evaluation: Prior to and during Epoetin therapy, the patient’s iron stores, including transferrin saturation and serum ferritin, should be evaluated. Transferrin saturation should be at least 20%, and ferritin should be at least 100 ng/mL. Virtually all patients will require supplemental iron to increase or maintain transferrin saturation to levels that will adequately support erythropoiesis.

Lactation: Unknown whether drug is excreted in breast milk; use with caution; avoid administering multidose vials

Side Effect

>10%
Pyrexia (10-42%),Nausea (11-35%),Hypertension (14-27%),Cough (4-26%),Vomiting (12-28%),Pruritus (12-21%),Rash (2-19%),Headache (5-18%),Arthralgias (10-16%)

1-10%
Arthralgia (10%),Myalgia (10%),Stomatitis (10%),Diarrhea (9%),Dizziness (9%),Edema (9%),Fatigue (9%),Weight decrease (9%),Medical device malfunction (artificial kidney clotting during dialysis) (8%),Vascular occlusion (vascular access thrombosis) (8%),Vomiting (8%),Asthenia (7%),Chest pain (7%),Injection-site irritation (7%),Muscle spasm (7%),Upper respiratory tract infection (URTI) (7%),Urticaria (3%),Seizures (2.5%),Pulmonary embolism (1%),Respiratory tract congestion (1%)

Potentially Fatal: Hypertensive crisis with encephalopathy-like symptoms e.g. headache, confusion, generalised seizures. Thrombosis.

Interaction

Haematinics enhance efficiency. Increased dose of heparin in patients undergoing dialysis.